Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

ADMCs-derived exosomal vesicles encapsulated with rifampicin to attenuate Klebsiella pneumonia-induced pediatric lung inflammation: In-vitro and In vivo studies.

Jia G., Dong Q., Song Z., Zhang B.

Animal Study on Chronic Wound, published in Microb Pathog (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Microb Pathog (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42269980
DOI
10.1016/j.micpath.2026.108625

Abstract (original English)

In the current scenario, Klebsiella pneumoniae-induced pediatric lung inflammation is a major health issue, made worse by multidrug-resistant infection. Mainly, Carbapenem-resistant K. pneumoniae (CR-K.pneu) infections are rising due to antimicrobial resistance, highlighting the urgent need for effective treatments. Additionally, lung inflammation can complicate the treatment of lung cancer, as it may hinder therapeutic responses. Herein, the study aimed to explore the adipose mesenchymal stem cells derived exosomal vesicles (ADMSCs-EVs) loaded with rifampcin (Rf) against CR-K. pneu infection in mice model. ADMSCs-EVs were extracted by the ultracentrifugation method and characterized via UV-visible spectra, FTIR, TEM, DLS and Zeta potential. It exhibited strong antioxidant potential confirmed via DPPH assays. The antibacterial assay was significantly inhibited at 100 μg/ml of ADMSCs-EVs-Rf against CR-K.pneu. Light microscopy displays biofilm eradication at the doses of 75 and 100 μg/ml. In vitro biocompatibility of ADMSCs-EVs-Rf enhances proliferation, suppresses oxidative stress, accelerates wound healing, and significantly attenuates inflammatory cytokine production in LPS-induced pediatric NHBE cells. Further, the in vivo antibacterial activity of ADMSCs-EVs-Rf was examined in a CR-K.pneu infection mice model. The treatment significantly decreased MDA levels while increasing

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsKlebsiella pneumoniaeKlebsiella InfectionsMesenchymal Stem CellsMiceExosomesHumansDisease Models, AnimalAnti-Bacterial AgentsRifampin

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research